Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

Virology

Volumn 444, Issue 1-2, 2013, Pages 329-336

  Barnard, Richard J O ^a   Howe, John A ^a   Ogert, Robert A ^a   Zeuzem, Stefan ^b   Poordad, Fred ^c   Gordon, Stuart C ^d   Ralston, Robert ^a   Tong, Xiao ^e   Sniukiene, Vilma ^a   Strizki, Julie ^a   Ryan, Desmond ^a   Long, Jianmin ^a   Qiu, Ping ^a   Brass, Clifford A ^a   Albrecht, Janice ^a   Burroughs, Margaret ^a   Vuocolo, Scott ^a   Hazuda, Daria J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

Boceprevir; HCV; RAV; Resistance; Variants

Indexed keywords

AMINO ACID; BOCEPREVIR; PLACEBO; RNA DIRECTED RNA POLYMERASE;

AMINO ACID ANALYSIS; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; GENE FUNCTION; GENE IDENTIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NONHUMAN; NONSTRUCTURAL PROTEIN 3 PROTEASE GENE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS GENOME; VIRUS LOAD;

BOCEPREVIR; HCV; RAV; RESISTANCE; VARIANTS;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MUTATION, MISSENSE; PROLINE; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84882876118     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.06.029     Document Type: Article

References (29)

1. Bacon B., Gordon S., Lawitz E., et al. Boceprevir for previously treated chronic HCVgenotype 1 infection. N. Engl. J. Med. 2011, 364(13):1207-1217.
2. Bartels D.J., Zhou Y., Zhang E.Z., et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 2008, 198(6):800-807.
3. Berman K., P.Y.Kwo Boceprevir an NS3 protease inhibitor of HCV. Clin. Liver Dis. 2009, 13(3):429-439.
4. Brau N., Bini E.J., Currie S., et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J. Viral. Hepat. 2006, 13(4):242-249.
5. Castro C, Arnold JJ, Cameron CE. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 2005, 107(2):141-149.
6. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gerolami R. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology 2008, 47(2):766-767.
7. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J. Virol. Methods 2008, 153(2):156-162.
8. Davis GL, Alter MJ, El Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521. 521.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
10. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46(3):631-639.
11. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
12. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 2006, 50(3):1013-1020.
13. McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008, 48(5):1700-1712.
14. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361(6):580-593.
15. Mederacke I, Wedemeyer H, Boceprevir Manns MP. an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr. Opin. Investig. Drugs 2009, 10(2):181-189.
16. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282(5386):103-107.
17. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586.
18. Poordad F, Bacon B, Bruno S, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Engl. J. Med. 2011, 364(13):1195-1206.
19. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143(3):608-618.
20. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2010, 2(30). 30ra32.
21. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132(4):1270-1278.
22. Schiff E, Poordad F, Jacobson IM, et al. Boceprevir(B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J. Hepatol. 2008, 48(2):S46.
23. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5(9):558-567.
24. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 2011, 140(2):667-675.
25. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50(6):1709-1718.
26. Sullivan J.C., De Meyer S., Bartels DJ., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57(2):221-229.
27. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006, 70(2):28-38.
28. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 2008, 77(3):177-185.
29. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5(11):610-622.